Trials / Unknown
UnknownNCT01887561
Dasatinib for Patients Achieving Complete Molecular Response for Cure D-NewS Trial
PhaseⅡClinical Trial of Dasatinib for Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase and Stop Therapy After Achieving Complete Molecular Response for Cure D-NewS
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Kanto CML Study Group · Academic / Other
- Sex
- All
- Age
- 15 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess whether dasatinib can be discontinued without occurrence of molecular relapse in patients with chronic myeloid leukemia in chronic phase in complete molecular remission(CMR) while on dasatinib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | dasatinib |
Timeline
- Start date
- 2012-11-01
- Primary completion
- 2012-12-01
- First posted
- 2013-06-27
- Last updated
- 2013-06-27
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01887561. Inclusion in this directory is not an endorsement.